Manish A Shah

Citado por

	Total	Desde 2019
Citas	31717	18523
Índice h	81	59
Índice i10	210	163

3800

1900

950

2850

20052006200720082009201020112012201320142015201620172018201920202021202220232024156 309 389 479 451 531 645 881 1049 1247 1459 1482 1603 1730 1994 2603 3151 3512 3425 3703

Acceso público

Ver todo

75 artículos

9 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

David IlsonProfessor of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Florian LordickUniversity Cancer Center LeipzigDirección de correo verificada de medizin.uni-leipzig.de
Yoon-Koo KangAsan Medical CenterDirección de correo verificada de amc.seoul.kr
Kohei ShitaraNational Cancer Center Hospital EastDirección de correo verificada de east.ncc.go.jp
Yung-Jue BangProfessorDirección de correo verificada de boconsulting.io
Jaffer AjaniUT M. D. Anderson Cancer CenterDirección de correo verificada de mdanderson.org
Mithat GönenMemorial Sloan-Kettering Cancer CenterDirección de correo verificada de alumni.stanford.edu
Eileen M. O'ReillyMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Allyson J OceanWeill Cornell Medical CollegeDirección de correo verificada de med.cornell.edu
Vivian E. StrongProfessor of Surgery, Memorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Yelena Y. Janjigian, MDMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
ANTOINE ADENISInstitut du Cancer de MontpellierDirección de correo verificada de icm.unicancer.fr
Daniel CatenacciAssociate Professor of MedicineDirección de correo verificada de bsd.uchicago.edu
David CunninghamThe Royal Marsden NHS Foundation TrustDirección de correo verificada de rmh.nhs.uk
Doron BetelAssistant Professor of Computational Biomedicine, Weill Cornell Medical CollegeDirección de correo verificada de med.cornell.edu
David KlimstraMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Elizabeth SmythOxford CancerDirección de correo verificada de nhs.net
Holly PrigersonProfessor of Medicine, Weill Cornell Medical CollegeDirección de correo verificada de med.cornell.edu
Prashant ThakkarWeill Cornell MedicineDirección de correo verificada de med.cornell.edu
Leonard SaltzProfessor of Medicine, Weill Cornell Medical College and Memorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org

Seguir

Manish A Shah

Weill Cornell, New York Hospital, Chair Solid Tumor Service, Co-Dir Cntr for Advanced Digestive Care

Dirección de correo verificada de med.cornell.edu - Página principal

Medical Oncology Drug Development Gastrointestinal Malignancies Gastric Cancer Esophageal Cancer


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes ME MacDonald, CM Ambrose, MP Duyao, RH Myers, C Lin, L Srinidhi, ... Cell 72 (6), 971-983, 1993	2297	1993
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013, 2018	1797	2018
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, A Tse, A Hamilton, ... Journal of clinical oncology 23 (9), 1803-1810, 2005	1428	2005
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study A Ohtsu, MA Shah, E Van Cutsem, SY Rha, A Sawaki, SR Park, HY Lim, ... Journal of clinical oncology 29 (30), 3968-3976, 2011	1388	2011
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study JM Sun, L Shen, MA Shah, P Enzinger, A Adenis, T Doi, T Kojima, ... The Lancet 398 (10302), 759-771, 2021	1061	2021
Targeting the cell cycle: a new approach to cancer therapy GK Schwartz, MA Shah Journal of clinical oncology 23 (36), 9408-9421, 2005	1000	2005
Oesophageal cancer EC Smyth, J Lagergren, RC Fitzgerald, F Lordick, MA Shah, P Lagergren, ... Nature reviews Disease primers 3 (1), 1-21, 2017	953	2017
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020	843	2020
Gastric cancer epidemiology and risk factors DE Guggenheim, MA Shah Journal of surgical oncology 107 (3), 230-236, 2013	725	2013
Chemotherapy use, performance status, and quality of life at the end of life HG Prigerson, Y Bao, MA Shah, ME Paulk, TW LeBlanc, BJ Schneider, ... JAMA oncology 1 (6), 778-784, 2015	656	2015
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial E Van Cutsem, S de Haas, YK Kang, A Ohtsu, NC Tebbutt, J Ming Xu, ... Journal of clinical oncology 30 (17), 2119-2127, 2012	596	2012
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma MA Shah, RK Ramanathan, D Ilson, ... Journal of Clinical Oncology 24 (33), 5201-5206, 2006	584	2006
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy MA Shah, GK Schwartz Clinical cancer research 7 (8), 2168-2181, 2001	561	2001
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an … PC Thuss-Patience, MA Shah, A Ohtsu, E Van Cutsem, JA Ajani, H Castro, ... The lancet oncology 18 (5), 640-653, 2017	539	2017
Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019	466	2019
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised … J Tabernero, PM Hoff, L Shen, A Ohtsu, MA Shah, K Cheng, C Song, ... The Lancet Oncology 19 (10), 1372-1384, 2018	450	2018
Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram VE Strong, KY Song, CH Park, LM Jacks, M Gonen, M Shah, DG Coit, ... Annals of surgery 251 (4), 640-646, 2010	399	2010
Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline EP Balaban, PB Mangu, AA Khorana, MA Shah, S Mukherjee, CH Crane, ... Journal of Clinical Oncology 34 (22), 2654-2668, 2016	398	2016
Infection of Orthopedic Prostheses after Staphylococcus aureus Bacteremia DR Murdoch, SA Roberts, VG Fowler Jr, MA Shah, SL Taylor, AJ Morris, ... Clinical infectious diseases 32 (4), 647-649, 2001	390	2001
Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline DPS Sohal, PB Mangu, AA Khorana, MA Shah, PA Philip, EM O’Reilly, ... Journal of Clinical Oncology 34 (23), 2784-2796, 2016	388	2016

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores